Stockscreener 앱 받기
43.59
9.14%
3.65
시간 외 거래:
43.60
0.010
+0.02%
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Global RNAi Technology Market: Opportunities in Targeted - openPR.com
Antisense Oligonucleotides Market is expected to reach US$ - openPR.com
Ionis announces leadership change as chief development officer plans retirement - Investing.com India
Ionis announces Dr. Richard Geary, chief development officer, to - GuruFocus
Ionis announces leadership change as chief development officer plans retirement By Investing.com - Investing.com South Africa
JP Morgan Maintains Neutral Rating, Raises Price Target for Ionis Pharmaceuticals (IONS) | IONS Stock News - GuruFocus
Analyst Expectations For Ionis Pharmaceuticals's Future - Benzinga
Ionis Pharmaceuticals (IONS) Announces Leadership Change in Development | IONS Stock News - GuruFocus
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Announces Dr Richard Geary, Chief Development Officer, To Retire - MarketScreener
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026 - The Joplin Globe
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits - Quantisnow
JPMorgan Adjusts Ionis Pharmaceuticals (IONS) Price Target to $4 - GuruFocus
JPMorgan Adjusts Ionis Pharmaceuticals (IONS) Price Target to $48 | IONS Stock News - GuruFocus
Ionis doses first subject in Phase III trial of Angelman syndrome therapy - Yahoo Finance
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome | IONS Stock News - GuruFocus
Ionis begins phase 3 trial of Angelman syndrome treatment By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (IONS) Advances with Phase 3 REVEAL Study for Angelman Syndrome | IONS Stock News - GuruFocus
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome - Yahoo Finance
Ionis Pharmaceuticals reports annual meeting results - Investing.com Australia
Ionis Pharmaceuticals reports annual meeting results By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Day 8 of Gains Streak for Ionis Pharmaceuticals Stock with 13% Return (vs. 5.1% YTD) [6/9/2025] - Trefis
Breakthrough Growth in Transthyretin Amyloid Cardiomyopathy - openPR.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Ionis Pharmaceuticals (NASDAQ:IONS) versus Akero Therapeutics (NASDAQ:AKRO) Financial Contrast - Defense World
Transcript : Ionis Pharmaceuticals, Inc.Shareholder/Analyst Call - marketscreener.com
10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report? - Yahoo Finance
We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed - simplywall.st
Transthyretin Amyloid Cardiomyopathy Treatment Market Deep Research ReportPfizer, Ionis Pharmaceuticals - openPR.com
Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Ionis Pharmaceuticals’ SWOT analysis: RNA therapeutics firm faces pivotal year for stock - Investing.com
Angioedema Treatment Market Insights and Forecast from 2025 - openPR.com
Hereditary Angioedema Drugs Market 2034: EMA, PDMA, FDA - openPR.com
D. E. Shaw & Co. Inc. Reduces Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Ionis’ olezarsen shows new promise with strong Phase III results - The Pharma Letter
December 2027 Options Now Available For Ionis Pharmaceuticals (IONS) - Nasdaq
Ionis reports success in olezarsen trial for high triglycerides - Yahoo
Treatment-Resistant Hypertension Market: Epidemiology, - openPR.com
Ionis Pharmaceuticals (NASDAQ:IONS) Earns Buy Rating from HC Wainwright - Defense World
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
Hereditary Angioedema Market Set to Grow Substantially Through - openPR.com
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Transcript : Ionis Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 08 - marketscreener.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by Janus Henderson Group PLC - Defense World
Ionis reports positive data from study of olezarsen for hypertriglyceridemia - Clinical Trials Arena
1.45%
0.86%
자본화:
|
볼륨(24시간):